on MetaTech AP Inc.
MetaTech AP Reveals 2027 Strategy, Partners with Zheng Yang Biomedical
On October 15, 2026, MetaTech AP Inc. announced its 2027 growth strategy, highlighting key partnerships and market forecasts. The company's revenue for the first nine months of 2026 reached NT$1.391 billion, marking a 21% increase from the previous year. This growth is driven by expansion in electronics and biomedicine sectors.
MetaTech AP reported a 24.7% increase in its electronics business, focusing on AI servers, power supplies, and semiconductors. Meanwhile, the company's venture into regenerative medicine, initiated in 2013, has yielded advancements in cell therapy technologies.
The new partnership with Zheng Yang Biomedical aims to build a regenerative medicine supply chain. MetaTech AP will manufacture human platelet lysate, while Zheng Yang will handle global sales. They are also collaborating on Elate Ocular®, targeting the dry eye disease market projected to grow significantly by 2028.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MetaTech AP Inc. news